相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venetoclax: a new weapon to treat high-risk CLL
Davide Rossi
LANCET ONCOLOGY (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia
Romain Guieze et al.
BLOOD (2015)
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
David M. Kurtz et al.
BLOOD (2015)
Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients
S. Q. Wong et al.
BRITISH JOURNAL OF CANCER (2015)
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas
Stephen Q. Wong et al.
CANCER RESEARCH (2015)
Emerging immunological drugs for chronic lymphocytic leukemia
Pawel Robak et al.
EXPERT OPINION ON EMERGING DRUGS (2015)
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
Mark Roschewski et al.
LANCET ONCOLOGY (2015)
Mutations driving CLL and their evolution in progression and relapse
Dan A. Landau et al.
NATURE (2015)
multiSNV: a probabilistic approach for improving detection of somatic point mutations from multiple related tumour samples
Malvina Josephidou et al.
NUCLEIC ACIDS RESEARCH (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data
F. Favero et al.
ANNALS OF ONCOLOGY (2015)
IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patients
Jian He et al.
Oncotarget (2015)
PEAR: a fast and accurate Illumina Paired-End reAd mergeR
Jiajie Zhang et al.
BIOINFORMATICS (2014)
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
Jennifer A. Woyach et al.
BLOOD (2014)
Inferring copy number and genotype in tumour exome data
Kaushalya C. Amarasinghe et al.
BMC GENOMICS (2014)
DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly
Ilari Scheinin et al.
GENOME RESEARCH (2014)
Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
A. C. Rawstron et al.
LEUKEMIA (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A simple consensus approach improves somatic mutation prediction accuracy
David L. Goode et al.
GENOME MEDICINE (2013)
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2012)
The Life History of 21 Breast Cancers
Serena Nik-Zainal et al.
CELL (2012)
Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis
Davide Rossi et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
Sebastian Boettcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
Victor Quesada et al.
NATURE GENETICS (2012)
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
Davide Rossi et al.
BLOOD (2011)
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2011)
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Lili Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Minimal residual disease in chronic lymphocytic leukaemia:: is it ready for primetime?
Chadi Nabhan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
分享论文
